| Typicality: | 0.274 |
| Saliency: | 0.057 |
| during the second or third trimester | 4 | temporal |
| exclusively | 2 | degree |
| pregnancy → be exposed to → trastuzumab | 4 |
| negative | neutral | positive |
| 0.434 | 0.542 | 0.025 |
| Raw frequency | 4 |
| Normalized frequency | 0.057 |
| Modifier score | 0.500 |
| Perplexity | 118.250 |